Immunotherapy combo may keep rare head and neck cancer at bay
NCT ID NCT03313206
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving the immunotherapy drug pembrolizumab before and after surgery can help prevent head and neck mucosal melanoma from coming back. About 60 adults with resectable tumors will receive pembrolizumab, then surgery and possibly radiation, followed by more pembrolizumab. The main goal is to see how long participants remain cancer-free after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pembrolizumab (an immunotherapy drug that helps the immune system fight cancer)
- What this could lead to
- If successful, this approach could improve the chances of keeping head and neck mucosal melanoma from coming back after surgery.
- What could go wrong
- This is a Phase 2 trial with only 60 participants, so results are preliminary. Immunotherapy can cause side effects like inflammation in healthy organs, and the cancer may still return.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK MUCOSAL MELANOMAS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Gustave Roussy
Villejuif, Val De Marne, 94805, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.